Compare Abeona Therapeutics Inc (ABEO) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs United Airlines Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while United Airlines Holdings Inc trades at $126.9 (market cap $40.17B). The key difference: United Airlines Holdings Inc is far larger — about 94.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | UAL | |
|---|---|---|
Market Cap | $424.33M | $40.17B |
Sector | Health | Industrials |
52-Week High | $7.45 | $136.11 |
52-Week Low | $4.17 | $85.21 |
Enterprise Value | $279.23M | $57.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
United Airlines (UAL) trades at $129.56, up 0.34% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $59.07B in 2025 and a net income margin of 5.56%, while valuation metrics like a P/E of 12.13 suggest potential undervaluation. Recent news highlights fleet innovation focus after merger attempts failed, with analyst consensus strongly bullish.
The outlook for UAL is positive, driven by sustained travel demand and cost management, but risks include fuel price volatility and competitive pressures. With 66% of analysts rating it Buy and a consensus price target of $167.73, the stock offers upside, though investors must monitor execution on fuel cost recapture and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
